secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2026-01-23T23:59:59+00:00
Accession:  0001104659-26-006015
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix CFO Donald Notman takes temporary medical leave; Jason Robins appointed interim CFO
--------------------------------------------------------------------------------

- Effective Jan 20, 2026, CFO/COO Donald Notman on temporary leave; Jason Robins named interim CFO and principal financial/accounting officer.
- Robins granted option to purchase 33,000 shares at $11.45/share, vesting monthly over four years.
- Robins, age 49, was SVP Finance since Jan 2025; previously VP Finance at Fusion Pharmaceuticals (acquired by AstraZeneca).
- No family relationships or related party transactions with Robins; standard indemnification agreement executed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465926006015/0001104659-26-006015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465926006015/tm263902d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-006015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer